NA CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 23
2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 DBMR TRIPOD DATA VALIDATION MODEL 29
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.6 MULTIVARIATE MODELLING 33
2.7 CLASS SEGMENT LIFELINE CURVE 33
2.8 DBMR MARKET POSITION GRID 34
2.9 VENDOR SHARE ANALYSIS 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 SECONDARY SOURCES 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 43
4.1 PESTEL 44
4.2 PORTER'S FIVE FORCES MODEL 45
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE) 46
6 EPIDEMIOLOGY 49
7 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO 50
8 PIPELINE ANALYSIS FOR NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS 52

9 MARKET OVERVIEW 53
9.1 DRIVERS 55
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 55
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT 57
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS 58
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC 58
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS 58
9.2 RESTRAINTS 59
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS 59
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS 59
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH 60
9.2.4 AVAILABILITY OF ALTERNATIVES 60
9.3 OPPORTUNITIES 60
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 60
9.3.2 RISE IN HEALTHCARE EXPENDITURE 61
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS 61
9.4 CHALLENGES 62
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS 62
9.4.2 STRINGENT REGULATIONS 62
10 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS 64
10.1 OVERVIEW 65
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN 68
10.2.1 BIOMEDICAL DIAGNOSTICS 69
10.2.2 AGRICULTURAL APPLICATIONS 69
10.2.3 GENOME ENGINEERING 69
10.2.4 DRUG DISCOVERY 69
10.2.5 OTHERS 69
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS 70

11 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 71
11.1 OVERVIEW 72
11.2 PRODUCTS 75
11.2.1 ASSAY KITS 76
11.2.1.1 SGRNA KIT 76
11.2.1.2 GENOMIC DETECTION KIT 76
11.2.1.3 OTHERS 77
11.2.2 PROTEINS 77
11.2.2.1 CAS9 77
11.2.2.2 CPF1 77
11.2.2.3 OTHERS 77
11.2.3 PLASMID AND VECTOR 78
11.2.4 LIBRARY 78
11.2.5 CONTROL KITS 78
11.2.6 DELIVERY SYSTEM PRODUCTS 78
11.2.7 DESIGN TOOLS 78
11.2.8 GENOMIC RNA 78
11.2.9 HDR BLOCKERS 78
11.2.9.1 AZIDOTHYMIDINE 79
11.2.9.2 TRIFLUOROTHYMIDINE 79
11.2.9.3 OTHERS 79
11.2.9.4 OTHERS 79
11.3 SERVICES 79
11.3.1 G-RNA DESIGN 80
11.3.2 CELL LINE ENGINEERING 80
11.3.3 MICROBIAL GENE EDITING 80
11.3.4 DNA SYNTHESIS 81
11.3.5 OTHERS 81

12 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION 82
12.1 OVERVIEW 83
12.2 BIOMEDICAL DIAGNOSTICS 86
12.2.1 CANCER 87
12.2.2 BLOOD DISORDERS 87
12.2.3 HEREDITARY DISORDERS 87
12.2.4 MUSCULAR DYSTROPHY 87
12.2.5 AIDS 87
12.2.6 NEURODEGENERATIVE CONDITION 87
12.2.7 OTHERS 88
12.3 AGRICULTURAL APPLICATIONS 88
12.4 GENOME ENGINEERING 88
12.4.1 CELL LINE ENGINEERING 89
12.4.2 HUMAN STEM CELLS 89
12.5 DRUG DISCOVERY 90
12.6 OTHERS 91
13 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW 92
13.1 OVERVIEW 93
13.2 CRRNA 96
13.3 CAS ENZYME 96
13.4 PRE-AMPLIFICATION 97
13.4.1 PCR 98
13.4.2 LAMP 98
13.4.3 RPA 98
13.5 SAMPLE PREPARATION 98
13.6 SENSING 99
13.6.1 FLUORESCENT PROBES 100
13.6.2 COLORIMETRIC 100
14 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER 101
14.1 OVERVIEW 102
14.2 BIOTECHNOLOGY COMPANIES 105
14.3 ACADEMIC AND RESEARCH INSTITUTES 106
14.4 DIAGNOSTIC CENTERS 107
14.5 HOSPITALS 108
14.6 OTHERS 109
15 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 110
15.1 OVERVIEW 111
15.2 DIRECT TENDER 115
15.3 RETAIL SALES 116
16 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION 117
16.1 NORTH AMERICA 118
16.1.1 U.S. 127
16.1.2 CANADA 132
16.1.3 MEXICO 137
17 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE 142
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 142
18 SWOT ANALYSIS 143
19 COMPANY PROFILE 144
19.1 THERMO FISHER SCIENTIFIC INC. 144
19.1.1 COMPANY SNAPSHOT 144
19.1.2 REVENUE ANALYSIS 144
19.1.3 COMPANY SHARE ANALYSIS 145
19.1.4 PRODUCT PORTFOLIO 145
19.1.5 RECENT DEVELOPMENTS 146
19.2 MERCK KGA 147
19.2.1 COMPANY SNAPSHOT 147
19.2.2 REVENUE ANALYSIS 147
19.2.3 COMPANY SHARE ANALYSIS 148
19.2.4 PRODUCT PORTFOLIO 148
19.2.5 RECENT DEVELOPMENTS 149
19.3 AGILENT TECHNILOGIES, INC 151
19.3.1 COMPANY SNAPSHOT 151
19.3.2 REVENUE ANALYSIS 151
19.3.3 COMPANY SHARE ANALYSIS 152
19.3.4 PRODUCT PORTFOLIO 152
19.3.5 RECENT DEVELOPMENT 153

19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 154
19.4.1 COMPANY SNAPSHOT 154
19.4.2 REVENUE ANALYSIS 154
19.4.3 COMPANY SHARE ANALYSIS 155
19.4.4 PRODUCT PORTFOLIO 155
19.4.5 RECENT DEVELOPMENTS 156
19.5 GENSCRIPT 157
19.5.1 COMPANY SNAPSHOT 157
19.5.2 REVENUE ANALYSIS 157
19.5.3 COMPANY SHARE ANALYSIS 158
19.5.4 PRODUCT PORTFOLIO 158
19.5.5 RECENT DEVELOPMENT 159
19.6 10 X GENOMICS 160
19.6.1 COMPANY SNAPSHOT 160
19.6.2 REVENUE ANALYSIS 160
19.6.3 PRODUCT PORTFOLIO 161
19.6.4 RECENT DEVELOPMENTS 161
19.7 APPLIED STEM CELL 162
19.7.1 COMPANY SNAPSHOT 162
19.7.2 PRODUCT PORTFOLIO 162
19.7.3 RECENT DEVELOPMENT 162
19.8 ADDGENE 163
19.8.1 COMPANY SNAPSHOT 163
19.8.2 PRODUCT PORTFOLIO 163
19.8.3 RECENT DEVELOPMENT 163
19.9 BIOVISION INC. 164
19.9.1 COMPANY SNAPSHOT 164
19.9.2 PRODUCT PORTFOLIO 164
19.9.3 RECENT DEVELOPMENT 165
19.10 CELLECTA, INC 166
19.10.1 COMPANY SNAPSHOT 166
19.10.2 PRODUCT PORTFOLIO 166
19.10.3 RECENT DEVELOPMENTS 167
19.11 CAS TAG BIOSCIENCES 168
19.11.1 COMPANY SNAPSHOT 168
19.11.2 PRODUCT PORTFOLIO 168
19.11.3 RECENT DEVELOPMENT 168

19.12 GENECOPOEIA, INC. 169
19.12.1 COMPANY SNAPSHOT 169
19.12.2 PRODUCT PORTFOLIO 169
19.12.3 RECENT DEVELOPMENT 169
19.13 HORIZON DISCOVERY LTD 170
19.13.1 COMPANY SNAPSHOT 170
19.13.2 PRODUCT PORTFOLIO 170
19.13.3 RECENT DEVELOPMENTS 171
19.14 HERA BIOLABS 172
19.14.1 COMPANY SNAPSHOT 172
19.14.2 PRODUCT PORTFOLIO 172
19.14.3 RECENT DEVELOPMENT 173
19.15 NEW ENGLAND BIOLABS 174
19.15.1 COMPANY SNAPSHOT 174
19.15.2 PRODUCT PORTFOLIO 174
19.15.3 RECENT DEVELOPMENTS 175
19.16 ORIGENE TECHNOLOGIES, INC. 176
19.16.1 COMPANY SNAPSHOT 176
19.16.2 PRODUCT PORTFOLIO 176
19.16.3 RECENT DEVELOPMENT 177
19.17 SYNTHEGO 178
19.17.1 COMPANY SNAPSHOT 178
19.17.2 PRODUCT PORTFOLIO 178
19.17.3 RECENT DEVELOPMENTS 178
19.18 TAKARA BIO INC. 180
19.18.1 COMPANY SNAPSHOT 180
19.18.2 REVENUE ANALYSIS 180
19.18.3 PRODUCT PORTFOLIO 181
19.18.4 RECENT DEVELOPMENT 181
19.19 TOOLGEN, INC. 182
19.19.1 COMPANY SNAPSHOT 182
19.19.2 PRODUCT PORTFOLIO 182
19.19.3 RECENT DEVELOPMENT 182
20 QUESTIONNAIRE 183
21 RELATED REPORTS 186